The influence of enteral feedings on sustained-release theophylline absorption

P. M. Plezia, S. M. Thornley, T. H. Kramer, Edward P Armstrong

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

In a randomized, crossover study the influence of enteral feedings (Ensure) on the absorption of theophylline from a sustained-release preparation (Theo-24) was evaluated. Six healthy, male subjects, age 22 to 37 years, participated. In phase 1 the subjects received a single oral dose of Theo-24 6 mg/kg with 100 ml of water at 8:00 A.M. In phase 2, they received 100 ml boluses of Ensure hourly, beginning 3 hours prior to the oral dose and continuing for a total of 1000 ml. In phase 3, subjects received a single 30-minute intravenous infusion of an equivalent dose of aminophylline. After each dose, serial blood samples were collected for 72 hours. No statistically significant differences in area under the curve (AUC0(∞)) (126.0 vs 127.3 μg hr/ml), maximum concentration (3.80 vs 4.08 μg/ml), or time to peak plasma level (13 vs 11 hrs) were found between phases 1 and 2. Mean AUC0(∞) for the intravenous phase (161.4 μg hr/ml) was significantly higher than the AUC for either oral study (p < 0.05). The mean bioavailability was 81% for phase 1 and 80% for phase 2. Percent absorbed versus time plots revealed no difference in rate of absorption between treatments. We conclude that short-term administration of the enteral feeding Ensure does not influence the absorption of theophylline when administered as the sustained-release product Theo-24.

Original languageEnglish (US)
Pages (from-to)356-361
Number of pages6
JournalPharmacotherapy
Volume10
Issue number5
StatePublished - 1990

Fingerprint

Enteral Nutrition
Theophylline
Area Under Curve
Delayed-Action Preparations
Aminophylline
Intravenous Infusions
Cross-Over Studies
Biological Availability
Healthy Volunteers
Water
Ensure

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

The influence of enteral feedings on sustained-release theophylline absorption. / Plezia, P. M.; Thornley, S. M.; Kramer, T. H.; Armstrong, Edward P.

In: Pharmacotherapy, Vol. 10, No. 5, 1990, p. 356-361.

Research output: Contribution to journalArticle

Plezia, PM, Thornley, SM, Kramer, TH & Armstrong, EP 1990, 'The influence of enteral feedings on sustained-release theophylline absorption', Pharmacotherapy, vol. 10, no. 5, pp. 356-361.
Plezia, P. M. ; Thornley, S. M. ; Kramer, T. H. ; Armstrong, Edward P. / The influence of enteral feedings on sustained-release theophylline absorption. In: Pharmacotherapy. 1990 ; Vol. 10, No. 5. pp. 356-361.
@article{02836f3d31254578b7dddf3e08600e34,
title = "The influence of enteral feedings on sustained-release theophylline absorption",
abstract = "In a randomized, crossover study the influence of enteral feedings (Ensure) on the absorption of theophylline from a sustained-release preparation (Theo-24) was evaluated. Six healthy, male subjects, age 22 to 37 years, participated. In phase 1 the subjects received a single oral dose of Theo-24 6 mg/kg with 100 ml of water at 8:00 A.M. In phase 2, they received 100 ml boluses of Ensure hourly, beginning 3 hours prior to the oral dose and continuing for a total of 1000 ml. In phase 3, subjects received a single 30-minute intravenous infusion of an equivalent dose of aminophylline. After each dose, serial blood samples were collected for 72 hours. No statistically significant differences in area under the curve (AUC0(∞)) (126.0 vs 127.3 μg hr/ml), maximum concentration (3.80 vs 4.08 μg/ml), or time to peak plasma level (13 vs 11 hrs) were found between phases 1 and 2. Mean AUC0(∞) for the intravenous phase (161.4 μg hr/ml) was significantly higher than the AUC for either oral study (p < 0.05). The mean bioavailability was 81{\%} for phase 1 and 80{\%} for phase 2. Percent absorbed versus time plots revealed no difference in rate of absorption between treatments. We conclude that short-term administration of the enteral feeding Ensure does not influence the absorption of theophylline when administered as the sustained-release product Theo-24.",
author = "Plezia, {P. M.} and Thornley, {S. M.} and Kramer, {T. H.} and Armstrong, {Edward P}",
year = "1990",
language = "English (US)",
volume = "10",
pages = "356--361",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "5",

}

TY - JOUR

T1 - The influence of enteral feedings on sustained-release theophylline absorption

AU - Plezia, P. M.

AU - Thornley, S. M.

AU - Kramer, T. H.

AU - Armstrong, Edward P

PY - 1990

Y1 - 1990

N2 - In a randomized, crossover study the influence of enteral feedings (Ensure) on the absorption of theophylline from a sustained-release preparation (Theo-24) was evaluated. Six healthy, male subjects, age 22 to 37 years, participated. In phase 1 the subjects received a single oral dose of Theo-24 6 mg/kg with 100 ml of water at 8:00 A.M. In phase 2, they received 100 ml boluses of Ensure hourly, beginning 3 hours prior to the oral dose and continuing for a total of 1000 ml. In phase 3, subjects received a single 30-minute intravenous infusion of an equivalent dose of aminophylline. After each dose, serial blood samples were collected for 72 hours. No statistically significant differences in area under the curve (AUC0(∞)) (126.0 vs 127.3 μg hr/ml), maximum concentration (3.80 vs 4.08 μg/ml), or time to peak plasma level (13 vs 11 hrs) were found between phases 1 and 2. Mean AUC0(∞) for the intravenous phase (161.4 μg hr/ml) was significantly higher than the AUC for either oral study (p < 0.05). The mean bioavailability was 81% for phase 1 and 80% for phase 2. Percent absorbed versus time plots revealed no difference in rate of absorption between treatments. We conclude that short-term administration of the enteral feeding Ensure does not influence the absorption of theophylline when administered as the sustained-release product Theo-24.

AB - In a randomized, crossover study the influence of enteral feedings (Ensure) on the absorption of theophylline from a sustained-release preparation (Theo-24) was evaluated. Six healthy, male subjects, age 22 to 37 years, participated. In phase 1 the subjects received a single oral dose of Theo-24 6 mg/kg with 100 ml of water at 8:00 A.M. In phase 2, they received 100 ml boluses of Ensure hourly, beginning 3 hours prior to the oral dose and continuing for a total of 1000 ml. In phase 3, subjects received a single 30-minute intravenous infusion of an equivalent dose of aminophylline. After each dose, serial blood samples were collected for 72 hours. No statistically significant differences in area under the curve (AUC0(∞)) (126.0 vs 127.3 μg hr/ml), maximum concentration (3.80 vs 4.08 μg/ml), or time to peak plasma level (13 vs 11 hrs) were found between phases 1 and 2. Mean AUC0(∞) for the intravenous phase (161.4 μg hr/ml) was significantly higher than the AUC for either oral study (p < 0.05). The mean bioavailability was 81% for phase 1 and 80% for phase 2. Percent absorbed versus time plots revealed no difference in rate of absorption between treatments. We conclude that short-term administration of the enteral feeding Ensure does not influence the absorption of theophylline when administered as the sustained-release product Theo-24.

UR - http://www.scopus.com/inward/record.url?scp=0025153547&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025153547&partnerID=8YFLogxK

M3 - Article

C2 - 2122422

AN - SCOPUS:0025153547

VL - 10

SP - 356

EP - 361

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 5

ER -